NINA
actual LEQEMBI patient
Slow progression with LEQEMBI
In an 18-month study of people with early Alzheimer’s disease, LEQEMBI was proven to slow the progression of early Alzheimer's disease. Even though you cannot stop Alzheimer’s disease from getting worse, you can take steps to slow how fast it progresses. Early treatment with LEQEMBI can help you keep playing the roles you have for longer.
How progression was measured
A tool called the Clinical Dementia Rating (CDR) scale measured progression by asking people how Alzheimer’s disease impacted different abilities listed below. LEQEMBI was not proven to individually impact each of these abilities.
Remembering
Staying active
Knowing your way around
Completing daily tasks
Problem-solving
Doing activities independently
Who was included in the study?
1,795 people*
Ages 50 to 90
From different ethnic and racial backgrounds
With mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease
*The study was divided into 2 groups. One group took LEQEMBI (898 people), and the other group did not take LEQEMBI (897 people).
"I think having
HOPE AND BEING
POSITIVE IS
EVERYTHING."
Get to know Nina, an actual LEQEMBI patient,
and hear how her positive outlook led to a LEQEMBI discussion with her neurologist.